Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Procept (PRCT): 50% rise on high volume. Why? -- Ignore unavailable to you. Want to Upgrade?

To: polar bear who wrote (351)	2/4/1998 2:14:00 PM
From: Douglas	Respond to of 455

"The next step being planned is to test safety in sexually active couples." This is disappointing! No announcement of a Phase II start date and just another safety test. Sounds like another Phase I or PhaseI/II. What about efficacy?

To: polar bear who wrote (351)	2/4/1998 2:16:00 PM
From: Douglas	Read Replies (1) \| Respond to of 455

Results from the Procept Abstract were "A total of 36 subjects were recruited, 34 of whom completed the study. Irritation was reported in 12 (mild in 10). Colposcopy revealed a cervical abrasion in one subject and inflammation was seen in another subject in the post-exposure biopsy. No impact was seen on vaginal lactobacilli. Laboratory safety studies remained normal throughout." It is interesting to compare ML Laboratories gel (D2S) with PRO 2000. Both were tested by the British Medical Research Council. The D2S results were published in the Autumn 1997 issue of the MRC News. "A study of 36 women volunteers using D2S intravaginal gel has shown that this agent does not cause any inflammation and preserves normal vaginal bacteria." I think the key words are "does not cause any inflammation"! Can anyone explain the difference between irritation and inflammation?